Gliptazit M (Tablets)

Description

Understanding Gliptazit M
 Gliptazit M, developed by Sanchem, is presumed to be a fixed-dose combination of a DPP-4 inhibitor and Metformin, used to manage type 2 diabetes mellitus.

How It Works
 The DPP-4 inhibitor component blocks the enzyme dipeptidyl peptidase-4, extending the action of incretin hormones (GLP-1 and GIP), which enhance glucose-dependent insulin secretion and suppress glucagon release. Metformin decreases hepatic glucose production, decreases intestinal glucose absorption, and improves peripheral insulin sensitivity.

Common Areas of Use
 Type 2 diabetes mellitus, particularly for patients requiring additional glycemic control beyond Metformin monotherapy, as prescribed by a physician.

Dosage and Administration
 Typically taken with meals to reduce gastrointestinal side effects. Dosage is individualized based on glycemic control, renal function, and patient response.

Safety Information
 Gliptazit M is contraindicated in significant renal impairment (due to Metformin-associated lactic acidosis risk), acute or chronic metabolic acidosis, and known hypersensitivity to either component. Caution is advised in patients with a history of pancreatitis. Patients should disclose kidney function status, alcohol use, other medications, and any planned imaging procedures requiring contrast dye.

Quality You Can Trust
 Every batch of Gliptazit M is manufactured in a GMP-compliant facility, with rigorous testing to ensure consistent potency and stability.

Why Choose Sanchem's Gliptazit M
 Gliptazit M reflects Sanchem's commitment to providing effective, well-manufactured therapies to support glycemic control in patients with type 2 diabetes.

A Note for Healthcare Professionals
 Sanchem welcomes healthcare providers to reach out for the specific gliptin component, dosing strengths, and full prescribing information for Gliptazit M.